Narnatumab
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer[1].
Product Specifications
CAS Number
1188275-92-4
Product Name Alternative
IMC-RON8; LY3012219; Anti-MSPR/RON/CD136 Reference Antibody (narnatumab)
UNSPSC
12352203
Target
C-Met/HGFR; Tyrosinase
Type
Inhibitory Antibodies
Related Pathways
Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/narnatumab.html
Purity
99.93
Solubility
H2O
Smiles
[Narnatumab]
Molecular Weight
(145.8 kDa)
References & Citations
[1]LoRusso PM, et, al. Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors. Invest New Drugs. 2017 Aug;35 (4) :442-450.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS7015956-01 0.02 mg
Recombinant Rift valley fever virus Envelope glycoprotein (GP)
Sign In for Pricing
View Details MBS7015956-02 0.1 mg
Recombinant Rift valley fever virus Envelope glycoprotein (GP)
Sign In for Pricing
View Details MBS7015956-03 5x 0.1 mg
Recombinant Rift valley fever virus Envelope glycoprotein (GP)
Sign In for Pricing
View Details